Acrivon therapeutics reports fourth quarter and full year 2022 financial results and business highlights

Watertown, mass., march 28, 2023 (globe newswire) -- acrivon therapeutics, inc. (“acrivon” or “acrivon therapeutics”) (nasdaq: acrv), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, today reported financial results for the fourth quarter and full year ended december 31, 2022 and reviewed business highlights.
ACRV Ratings Summary
ACRV Quant Ranking